Articles by Daniel Marsh
Eli Lilly Surge Lifts Healthcare ETF on GLP-1 Access and Drug Approval
Eli Lilly shares jumped 6.5% on Medicare GLP-1 access and a positive EU drug opinion, lifting the healthcare sector ETF XLV by 2.4%.
Nu Holdings Surges on Needham Buy Rating and US Expansion Prospects
Nu Holdings (NU) stock surged 6.3% after Needham started coverage with a Buy rating and $17 target, highlighting the company's Brazil scale and a possible US launch within 12 months.
Palantir Rebounds 5.5% Ahead of Russell Rebalance; Valuation Gap Narrows
Palantir Technologies (PLTR) jumped 5.5% amid heavy trading ahead of Friday's FTSE Russell reconstitution, recovering $15.2 billion in market value after a seven-session losing streak.
Moderna stock surges $3.3B after unveiling in vivo CAR-T for autoimmune disease
Moderna shares surged 13.9%, adding $3.3 billion in market value after the company unveiled an in vivo CAR-T candidate for autoimmune disease at its Science Day, though near-term sales remain absent.
Bloom Energy Plunges After Russell Index Switch
Bloom Energy shares fell 12.4% to $270.88 after exiting the Russell 2000 for the Russell Top 200, putting its high valuation under scrutiny amid heavy trading volume.
Ondas Shares Surge on Russell 3000 Entry and Resale Filing
Ondas shares jumped to $7.89 as the company joined the Russell 3000 index and filed to register 3.38 million acquisition-linked shares for resale, with daily volume caps.
Bradesco Shares Jump on 1.9% Payout, Loan Loss Concerns Linger
Bradesco shares surged 2.44% on heavy volume as a 1.9% interim dividend drew yield seekers, yet the stock remains 17% below its 52-week high amid rising loan-loss provisions.
Clearwater Analytics Delisted After $8.4B Take-Private, Options Settle for Cash
Clearwater Analytics' $8.4B take-private closed June 25 at $24.55/share, a 47% premium. CWAN delisted from NYSE; options settle for $2,455 cash per contract.
Sadot Group Shares Surge 75% on Massive Volume Amid Going Concern Doubts
Sadot Group (SDOT) soared 75% on volume 15x its share base, despite filings showing a tiny float, preferred stock, a large real estate option, zero Q1 commodity sales, and going concern doubts.
